Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABSK 061

Next Previous
Drug Profile

ABSK 061

Alternative Names: ABSK-061

Latest Information Update: 14 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbisko Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Achondroplasia

Most Recent Events

  • 07 May 2026 Pharmacodynamics data from a preclinical trials in Solid tumours released by Abbisko Therapeutics
  • 30 Mar 2026 US FDA approves IND application for ABSK 061 in Achondroplasia (In children)
  • 25 Mar 2026 ABSK 061 receives Orphan Drug status for Achondroplasia in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top